Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease

Key clinical point: High-dose aducanumab reduced clinical decline at 78 weeks in EMERGE.

Major finding: A 22% decrease in CDR-SB scores versus baseline was reported.

Study details: Two randomized, placebo-controlled studies involving a total of 3,285 participants.

Disclosures: Biogen sponsored the EMERGE and ENGAGE studies. The authors are Biogen employees.


Haeberlein SB et al. AAN 2020, Abstract 46977.